Intentional and non-intentional non-adherence to medication amongst breast cancer patients

Article English OPEN
Atkins, L. ; Fallowfield, L. J. (2006)

This study aimed to investigate the prevalence of and factors associated with non-adherence to medication amongst a sample of breast cancer patients. 131 women with stable disease were interviewed and completed standardised psychological measures. 55% of women reported non-adherence to medication frequently or occasionally, with younger women and those who disliked taking their medication being significantly less adherent (P = 0.015, P = 0.001). Women who deliberately omitted taking their tablets occasionally or frequently had significantly lower scores, indicative of a weaker influence, on 'internal' and 'powerful others' dimensions of health locus of control (P = 0.032, P = 0.009). Despite a life-threatening diagnosis, patients may not adhere to medication representing a potential missed opportunity for health gain and waste of resources. Furthermore, interpretation of clinical trial data may be misleading without adherence information. More research is needed to identify those at risk for non-adherence. If other routes of administration are available these options should be discussed with patients to maximise efficacy of therapy.
  • References (16)
    16 references, page 1 of 2

    Farmer K, Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clinical Therapeutics 1999; 21(6): 1074-1090.

    Horne RWeinman J, Patients' beliefs About prescribed medicines and their role In adherence to treatment in chronic physical illness. Journal of Psychosomatic Research 1999; 47(6): 555-567.

    Taylor. 1979, Baltimore: Johns Hopkins University Press.

    Powles T, Eeles R, Ashley S, et al., Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352(9122): 98-101.

    McDonald H, Garg A, Haynes R, Interventions to enhance patient adherence to medication prescriptions. Journal of the American Medical Association 2002; 288(22): 2868-2879.

    Elwyn G, Edwards A, Britten N, "Doing prescribing": how doctors can be more effective. British Medical Journal 2003; 327: 864-867.

    Fellowes D, Fallowfield L, Saunders C, Houghton J, Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res Treat 2001; 66(1): 73-81.

    Fink A, Gurwitz J, Radowski W, Guadagnoli E, Silliman R, Patient beliefs and tamoxifen discontinuation in older women with estrogen receptor-positive breast cancer. Journal of Clinical Oncology 2004; 22(16): 3309-3315.

    Fallowfield L, Fleissig A, Edwards R, et al., Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials. Journal of Clinical Oncology 2001; 19(7): 1885-1892.

    Demissie S, Silliman R, Lash T, Adjuvant Tamoxifen: Predictors of use, sideeffects, and discontinuation in older women. Journal of Clinical Oncology 2001; 19(2): 322-328.

  • Metrics
    No metrics available
Share - Bookmark